William D. Turner - 05 Apr 2022 Form 4 Insider Report for Sierra Oncology, Inc.

Role
Chief Reg & Tech Ops Officer
Signature
/s/ Mary Christina Thomson, Attorney-In-Fact for William D. Turner
Issuer symbol
N/A
Transactions as of
05 Apr 2022
Net transactions value
-$162,432
Form type
4
Filing time
07 Apr 2022, 16:12:48 UTC
Previous filing
22 Mar 2022
Next filing
17 Jun 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRRA Common Stock Options Exercise $1,205 +100 $12.05 100 05 Apr 2022 Direct
transaction SRRA Common Stock Sale $3,709 -100 -100% $37.09 0 05 Apr 2022 Direct F1
transaction SRRA Common Stock Options Exercise $76,481 +6,347 $12.05 6,347 06 Apr 2022 Direct
transaction SRRA Common Stock Sale $236,409 -6,347 -100% $37.25 0 06 Apr 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SRRA Stock Option (Right to Buy) Options Exercise $0 +100 $0.000000* 0 05 Apr 2022 Common Stock 100 $12.05 Direct F2
transaction SRRA Stock Option (Right to Buy) Options Exercise $0 +6,347 $0.000000* 0 06 Apr 2022 Common Stock 6,347 $12.05 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 19, 2021. The Reporting Person is subject to a Lock-Up Letter Agreement that expires on April 26, 2022. The sale of shares is a permissible exemption under the terms of the Lock-Up Letter Agreement.
F2 On August 4, 2021, the option vested as to 25% of the total shares granted on August 4, 2020, with the remaining shares from that grant vesting in equal monthly installments over the following 36 months, with 100% of the total shares vested on August 4, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.